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pare the two strategies, each using a Tenofovir-based backbone treatment. Effec-
tiveness was measured by virologic response, defined as the percentage of patients
with  50 viral copies/ml, based on a systematic review of recently published
prospective trials. Costs were estimated according to Belgian tariffs. Only direct
costs were considered, and were expressed in Euros (€). The time-horizon was of 48
weeks. A probabilistic sensitivity analysis was conducted to evaluate the robust-
ness of the results. RESULTS: Two prospective phase III trials were selected for
efficacy evaluation: data for Darunavir were extracted from the ARTEMIS trial (Mills
et cols.), whereas data for Atazanavir were extracted from the CASTLE trial (Molina
et cols.). Both compared the respectives drugs to Lopinavir. Based on an indirect
comparison, the rate of virologic response after 48 weeks of follow up was 84% (95%
CI: 82-86%) for Darunavir and 78% (95% CI: 76-80%) for Atazanavir, while total costs
were 5868,84€ and 4821,60€, respectively. The ICER was 18.011,04€ for Darunavir.
Sensitivity analysis showed that ICER depends mainly on the uni costs of the drugs,
as well as on their efficacy. However, it is relatively independant from side effects
and deaths related to treatment. CONCLUSIONS: Our results show that Darunavir,
used as the third agent (protease inhibitor), compared to Atazanavir, may be more
cost-effective for the treatment of naïve HIV-infected patients, in Belgium.
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OBJECTIVES: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. The elderly is a high risk (HR) population to develop IPD and this risk is raised
in the presence of chronic illness. This study aims to perform cost-effectiveness
analysis of 13-valent pneumococcal conjugated vaccine (PCV13) in elderly HR, from
a public payer perspective in Brazil. METHODS: A Markov model was developed to
simulate IPD outcomes in elderly HR after vaccination with PCV13 versus PPSV23
and no vaccination, with regard to associated direct costs in a 10-year time horizon.
Effectiveness parameters are avoided cases of IPD, meningitis, pneumonia, and
bacteremia. Medical costs included hospital days, medical personnel time, outpa-
tient visits, diagnostic tests and medications. Clinical data and costs were ex-
tracted from literature, presented in 2011USD. RESULTS: For an 1,000,000 patients
cohort, PCV13 avoided [14,159;14,885] bacteremia, [1,119;1,327] meningitis,
[190,831;198,098] hospitalized pneumonia, [153,569;150,599] non-hospitalized
pneumonia, and [56,102;58,686] IPD deaths, versus [PPSV23;no vaccination] respec-
tively. Medical and vaccination costs for PCV13 versus PPSV23 and no vaccination
were 7,901,973.76 BRL, 8,823,681.28 USD, and 8,327,792.71 USD, respectively. PCV13
was the dominant alternative in this cost-effectiveness analysis. CONCLUSIONS:
From the public payer perspective in Brazil, PCV13 showed to be dominant com-
pared to PPSV23 and no vaccination in elderly high risk population.
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OBJECTIVES: Hepatitis C is a disease with significant economic burden to health
care systems. Two recently approved protease inhibitors –telaprevir (TVR) and
boceprevir (BOC)- are expected to change the current treatment algorithm, since
their addition to peginterferon and ribavirin (PR) is associated with significantly
improved clinical outcomes compared to PR alone. This analysis aims to evaluate
the cost-effectiveness of a triple regimen with telaprevir (TVRPR) compared to
one with boceprevir (BOCPR) from the Greek National Health Service perspective.
METHODS: A decision analytic model based on treatment pathways and efficacy
data from four phase III clinical trials (Advance, Sprint-2, Realize and Respond-2)
was used to assess the cost-effectiveness of TVRPR and BOCPR . Clinical out-
come was measured in terms of sustained virologic response (SVR) rates. Drug
costs were estimated based on available EU prices in March 2012. We estimated the
average cost per cured (SVR) patient and ICERs over treatment naïve and experi-
enced patients and over the overall HCV G1 population (with a ratio of 1 to 4).
Treatment stopping rules were not considered in this analysis. One way sensitivity
analysis was performed over the proportion of naïve patients. Resource allocation
implications were also considered under a hypothetical fixed budget scenario.
RESULTS: The average cost per cured patient in the overall HCV G1 population was
€46.635 for TVRPR and €56.146 for BOCPR. In treatment naïve patients it was
€38.868 for TVRPR and €42.983 for BOCPR, whereas in treatment experienced
patients it was €48.966 and €59.902 respectively. In terms of ICERs TVRPR was
associated with lower costs and higher SVR rates, with an ICER of - €10.403 per
cured patient gained in the overall patient population. Results were robust in sen-
sitivity analysis. CONCLUSIONS: TVRPR was projected to be cost-effective com-
pared to BOCPR, allowing for more patients to be cured under a hypothetical fixed
budget.
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OBJECTIVES: After infection, varicella-zoster-virus can reactivate as herpes zoster
(HZ), a painful skin rash most commonly among the elderly. A HZ-complication is
long-lasting pain after rash disappearance: postherpetic neuralgia (PHN). A vaccine
has been licensed in Europe to prevent HZ/PHN in individuals aged 50 years. To
support decision-making concerning a possible vaccination-recommendation in
Germany we performed a health economic evaluation.METHODS:We developed a
5-state Markov-model with age-specific transition probabilities. We compared a
vaccination-strategy to a scenario without vaccination targeting different popula-
tion-cohorts aged 50 in Germany (50-54, 55-59, etc.) to identify the most cost-
effective strategy. Besides the payer-perspective (PP), the societal-perspective (SP)
- covering in addition to direct also indirect costs - was considered. Country-spe-
cific demographic, epidemiological, and cost-of-illness input-data were utilized.
We assumed a vaccine price of 100 Euro/dose, lifelong duration of protection, and
20% vaccination-coverage. All monetary amounts were in Euro 2010. The cycle-
length was a quarter, and the model ended when individuals died. The discount-
rate was 3% for both, outcomes and costs. Outcomes were number of HZ- and
PHN-cases avoided. Results were presented as incremental cost-effectiveness ra-
tios (ICERs) and number-needed-to-vaccinate (NNV). Univariate deterministic sen-
sitivity-analyses (DSA) were performed. RESULTS: When targeting a cohort aged
50-54 years, preventing one HZ-case costs approximately 400€ from PP and approx-
imately 280€ from SP. In this age-cohort the NNV was 6. DSA showed that results
were most sensitive to target-age at vaccination, vaccine price, and discount rate.
When increasing the target-age to 85 year-olds, ICERs were 3,646€ (PP) and 3,634€
(SP) per adverted HZ-case, respectively, indicating a lower cost-effectiveness of
vaccination in this age-cohort; NNV increased to 37. When considering prevention
of PHN-cases ICERs became less favourable. CONCLUSIONS: Vaccination appears
as valuable prevention-option especially when targeting the 50-54-years age-co-
hort. However, target-age at vaccination, price, and duration of protection will be
key-factors in decision-making.
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OBJECTIVES: To study economic efficiency of three regimes for pharmacotherapy
of acute bronchitis. Apart from classic therapy the first and second regimes in-
cluded the usage of drugs of human recombinant interferon-a2b in the form of
suppositories. METHODS: Patients suffering from acute bronchitis were randomly
split into three groups comprising 50 people each. The first group got classic ther-
apy (mucolytics, vitamins, alkaline drinks, heat reduction drugs) and suppositories
of interferon-a2b (genferon) by 1 mln ME injected rectally twice a day for the period
of 5 days. The second group was cured with interferon (viferon) by 1 mln ME twice
a day for the period of 5 days. The third group got the classic therapy only. The
pharmacoeconomical analysis estimated the general treatment cost and minimi-
zation of expenses. RESULTS: The average period of overcoming acute bronchitis
took 9 days for the first two groups and 12 days for the third group. The average
period of temporary work disability lasted for 7 [6; 8] days for the first two groups
and 10 [9; 12] days for the third group. The general cost for the first group amounted
to € 168.9, 167.1 for the second group and € 230.4 for the third group. The minimi-
zation of expenses reached € 61.5 for the first group and € 63.3 for the second one in
comparison with the classic method. Considering minimal costs of drugs the min-
imization of expenses amounted to € 56.5 and € 61 respectively. Considering ex-
penses for antibacterial therapy the minimization of expenses when taking into
account the average costs of drugs reached € 62.1 and € 64.4 respectively.
CONCLUSIONS: As a result, the pharmacotherapy of acute bronchitis when using
interferon is more justified than the classic method of therapy.
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OBJECTIVES: To assess the cost-effectiveness of maternal triple-drug ART or infant
nevirapine to reduce HIV transmission during breastfeeding from HIV-infected
Malawian mothers, not meeting treatment guidelines for their own health. Strat-
egies were evaluated at two entry points into the health system: 1) time of delivery,
for mothers who have not accessed ART antenatally, and 2) antenatally.
METHODS: Cost-effectiveness was evaluated in terms of health care costs per HIV
transmission averted, life-years gained, quality adjusted life-years (QALYs) gained,
and disability adjusted life-years (DALYs) averted. The risks of HIV transmission
associated with the interventions were taken from the Kesho Bora and BAN stud-
ies. Antenatal regimens were 1) zidovudine (ZDV); 2) ZDV, lamivudine (3TC), lopi-
navir/ritonavir; and (3) no antenatal regimen. The postnatal regimens were 1) ma-
ternal antiretrovirals (ZDV, 3TC, lopinavir/ritonavir); 2) infant nevirapine (NVP);
and 3) no extended post-natal prophylaxis. Scenario analyses included: alternate
drug combinations and prices, and earlier antenatal initiation. RESULTS: For moth-
ers presenting at delivery, infant NVP during breastfeeding is likely to be consid-
ered cost-effective. Incremental cost-effectiveness ratios (ICERs) compared to stan-
dard of care are $264 per HIV transmission averted, $15 per life-year saved, $16 per
QALY and $15 per DALY averted. For mothers presenting antenatally, antenatal
ZDV plus infant NVP during breastfeeding appears cost-effective. ICERs compared
to ZDV plus standard of care are $667 per HIV transmission averted, $37 per life-
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year saved, $39 per QALY and $37 per DALY averted. CONCLUSIONS: For pregnant,
HIV-1 infected women presenting at delivery and not requiring antiretrovirals for
their own health, infant NVP throughout breastfeeding is likely to be considered
cost-effective. For those presenting antenatally, antenatal ZDV followed by infant
NVP throughout breastfeeding (WHO Option A) is likely to be considered cost-
effective.
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OBJECTIVES: To provide pharmacoeconomic evaluation of diagnostics of tubercu-
losis infection (TI) with Allergen tuberculosis recombinant (CFP10-ESAT6) and Al-
lergen tuberculosis purified liquid in the standard dilution for intradermal use (PPD
RT 23 SSI). METHODS: The cost-effectiveness analysis. In the study direct costs
included cost of TI diagnostics, cost of the additionally surveys, cost of observation
in the clinic and cost of treatment of TI patients. RESULTS: The efficacy of TI
diagnostics was evaluated. The frequency of diagnostics of active tuberculosis has
been evaluated on the data of the TI diagnostics in children and adolescents in
Moscow and Samara region. The proportion of patients with active tuberculosis
were 0.31%, 0.006% and 0.04% for CFP10-ESAT6, PPD RT 23 SSI and a combined
scheme of diagnostics (simulate situation when both drugs use), respectively. Di-
rect costs for TI diagnostics, surveillance and treatment of TI were calculated.
Direct costs amounted to 380.36 RUB (9.17 EUR), 218.18 RUB (5.26 EUR) and 220.46
RUB (5.31 EUR) for CFP10-ESAT6, PPD RT 23 SSI and combination scheme, on one
patient, respectively. Finally, total direct costs for the diagnostics one patient with
active tuberculosis were 122.687 RUB (2.956 EUR), 3.646.833 RUB (87.875 EUR) and
551.150 RUB (13.281 EUR), for the estimated diagnostic schemes, respectively.
CONCLUSIONS: The pharmacoeconomic study results shows, that CFP10-ESAT6 is
dominant technology from “cost-effectiveness” analysis perspective.
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OBJECTIVES: To highlight the different results obtained when conducting an eco-
nomic evaluation of RPV using response rates other than those in the SmPC.
METHODS: We considered the overall response rate of Rilpivirine (RPV) clinical
trials, and the response rates in the indicated population based on its SmPC (pa-
tients with baseline viral load  100.000 copies/ml). Efficacy was defined as the
percentage of patients having viral load  50 copies/ml at week 48 per intention-
to-treat analysis. The analysis perspective is that of the Spanish NHS, considering
in our model only the cost of the antiviral drug. Time horizon is 48 weeks and costs
are ex-factory prices (2012). Since the reimbursed price of RPV has not being ap-
proved in Spain yet, our base case assumes the hypothesis anticipated by some
Spanish HTAs that RPV could be priced as parity to the SoC, Efavirenz (EFV). Four
scenarios were performed: price parity, 2.5%, 5% and 7.5% premium price over
EFV.RESULTS: In the price parity scenario, depending on the response rate applied,
the cost per responder of RPV ranges from 3.575€ (SmPC efficacy rates) to 3.839€
(overall efficacy rates). It is estimated that HIV-1 incidence in Spain is around 2,600
new patients/year, 70% of whom would have baseline VL  100.000 copies/ml. In
the price parity scenario, since the difference in efficacy rates is 6.6% (1.6%; 11.5%)
IC 95% RPV vs EFV, initiating the treatment with RPV instead of EFV would allow to
successfully treat 120 patients more than with EFV.CONCLUSIONS: Economic eval-
uation should be conducted using response rates associated to the approved prod-
uct label to get the most accurate measure of true value. When doing so, our model
demonstrates that RPV would be more cost-effective than EFV in naïve patients
with baseline VL  100.000 copies/ml in the four scenarios analyzed.
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OBJECTIVES: Hepatitis C is an infection that when left untreated or unsuccessfully
treated, progresses into Advanced Liver Disease (ALD) associated with a high clin-
ical, humanistic and economic burden. Due to limited economic resources, health
care providers may have to choose whether to treat F2 patients with PR alone vs.
Telaprevir plus PR (TPR). This publication aims to demonstrate the clinical and
economic value of treating naïve F2 patients with TPR, a triple based regimen
compared to PR alone. METHODS: A post-hoc analysis of the phase III ADVANCE
was conducted and NNT were calculated. Cost-effectiveness of TPR vs. PR in F2
patients was determined based on a UK economic model. A cost per cure (SVR)
model analyzed the number of cured patients with TPR vs PR and number of pa-
tients treated but not cured. RESULTS: NNT in F2 patients was estimated to be 3.3.
In previously untreated F2 fibrosis patients, TPR was associated with higher costs
and improved outcomes compared to PR with an Incremental Cost Effectiveness
Ratio (ICER) of £ 9,930/ QALY. Treating 100 F2 patients with TPR results in 79 cured
patients compared with only 49 cured patients with PR. In order to achieve cure in 50
patients, 13 patients would be treated but not cured with TPR compared to 52 treated but
not cured with PR alone. With a million £ investment with TPR only 7 patients are not
cured compared to 53 patients with PR alone. CONCLUSIONS: TPR provides clinical
and economic value for F2 untreated patients. It is clinically superior treatment
versus PR, is a cost-effective treatment option and within a fixed budget choosing
TPR instead of PR results in more patients cured and in less treatment failures.
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OBJECTIVES: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. Pediatric high-risk population (PHR) (like sickle cell disease, HIV infected or
those receiving immunosuppressive medications) are 30-100 times more likely to
develop IPD compared to healthy children. This study aims to perform cost-effec-
tiveness analysis of 13-valent pneumococcal vaccine (PCV13) in PHR, from a public
payer perspective in Brazil. METHODS: A decision tree-model was developed to
simulate IPD outcomes in PHR after vaccination with PCV13 versus PCV10 and
non-vaccination and their associated direct costs in a 10-year time horizon. Despite
comparison with PCV10, this indication is off-label in Brazil and no studies are
available to this population segment. Effectiveness parameters are avoided cases
of IPD, hospitalized and non-hospitalized pneumonia. Direct medical costs in-
cluded hospital days, medical personnel time, outpatient visits, diagnostic tests
and medications. Clinical data and costs were extracted from literature, presented
in 2012 USD. Probabilistic sensitivity analyses were performed trough Monte Carlo
Simulation second-order approach. RESULTS: For a 611,737 patients cohort, PCV13
avoided [1,626; 1,851] IPD, [1,996; 92,805] hospitalized pneumonia, [1,585; 73,700]
non-hospitalized pneumonia, and [570; 649] IPD deaths, versus [PCV10; non-vacci-
nation]. Projected treatment costs for PCV13 versus PCV10 were 703,326,000USD,
and 707,410,000USD, respectively. For PCV13 versus non-vaccination projected
treatment costs was 367,000,000USD versus 705,000,000USD, respectively. In cost-
effectiveness analysis, PCV13 was cost-saving in all comparisons. CONCLUSIONS:
From the public payer perspective in Brazil, PCV13 showed to be dominant regard-
ing life years gained than PCV10 vaccination and non-vaccination strategy.
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OBJECTIVES: To estimate the cost per sustained virological response (SVR) in ge-
notype 1 (G1) hepatitis C (HCV) patients according to previous treatment response
and METAVIR groups in Brazil. METHODS: SVR and extended rapid virological
response (eRVR) rates were from the respective phase III clinical trials of telaprevir
(ADVANCE and REALIZE) and boceprevir (SPRINT-2 and RESPOND-2) for treatment
naive patients, METAVIR F0-F3 naive patients, and treatment experienced patients
(relapsers, partial responders and null responders). When SVR and eRVR rates were
not available for a patient subgroup these were assumed to be the same as the
global patient population. Brazilian treatment costs were based on the eRVR rates
and calculated based on the prices for telaprevir and boceprevir recently published
by the HTA body CONITEC. Treatment costs for pegylated interferon and ribavirin
were calculated from the reimbursed price published in the official website:
www.comprasnet.gov.br. RESULTS: Telaprevir has the lowest cost-SVR for all pa-
tients in the analysis compared to boceprevir. In treatment naive patients, telapre-
vir has a cost-SVR of R$ 64.513 compared to boceprevir with R$ 72.275. In METAVIR
scale of F0-F3 treatment naive patients, telaprevir has a lower cost-SVR of R$
64.196, while the cost-SVR for boceprevir remains 12% higher (R$ 72.275). The low-
est cost-SVR was observed for the prior relapse patients treated with telaprevir, R$
51.283/SVR, compared to boceprevir with R$ 58.736/SVR. Boceprevir has the highest
cost-SVR at R$ 90.658 compared to R$68.144 with telaprevir for patients with a
previous partial response. For prior null-responders, telaprevir is the only option
since as these patients were not studied with boceprevir. CONCLUSIONS: Telapre-
vir has the lowest cost-SVR compared to boceprevir for the treatment of hepatitis C
G1 patients in Brazil regardless of baseline disease severity and prior treatment
response.
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OBJECTIVES: To assess the cost-effectiveness of amoxicillin clavunate compared
to amoxicillin at primary care level in Turkey for community acquired pneumonia,
acute rhinosinusitis, tonsillopharyngitis, and acute otitis media. METHODS: As
proposed by the guidelines for the treatment of diseases costs have been deter-
mined through applying cost of illness methodology. The agents have been calcu-
lated by evaluating all brands and forms over continuous doses. The perspective of
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